Skip to content Skip to sidebar Skip to footer
Centuria Industrial
Centuria Industrial REIT (ASX:CIP) Declares 4.2 Cent Distribution: Is This a Buy?
Centuria Industrial REIT's Latest Distribution Centuria Industrial REIT (ASX: CIP) has announced a distribution of 4.2 cents per unit for the quarter ending December 31. What caught our attention isn't just the steady payout; it's the context around it. The REIT has kept its distribution reinvestment plan (DRP) suspended while running an active buyback program.…
battery-electric haul trucks
BHP and Rio Tinto Power Up Australia’s First Battery-Electric Haul Trucks in Major Decarbonisation Push
Introduction to Battery-Electric Haul Trucks Australia's first battery-electric haul trucks have arrived in the Pilbara, marking a significant milestone in the mining industry's push to eliminate diesel from iron ore operations. BHP (ASX: BHP) and Rio Tinto (ASX: RIO) are collaborating with Caterpillar to trial two Cat 793 XE Early Learner trucks at BHP's Jimblebar…
Mayne Pharma
Mayne Pharma (ASX: MYX) Threatens to Terminate A$672M Cosette Deal- Is the Stock a Buy at A$3.39?
The tables have turned, and shareholders face a key decision as the 10 December deadline approaches. Mayne Pharma (ASX: MYX) has turned the tables on US suitor Cosette Pharmaceuticals, issuing a termination notice alleging "wilful and intentional" breaches of their A$672 million takeover agreement. The Adelaide-based company, which spent much of 2025 fighting Cosette's attempts…
Saluda Medical
Saluda Medical (ASX:SLD) IPO Raises $230M, but Crashes 46% on its Trading Debut
Saluda Medical (ASX:SLD) listed on Friday after raising AU$230 million at AU$2.65 per share, marking a rare bright spot in an otherwise quiet year for ASX biotech debuts. Unlike most life sciences IPOs that arrive with little more than clinical-stage promise, Saluda Medical already generates US$70 million in annual revenue and is targeting US$82 million…
Telix
Optiscan Imaging (ASX: OIL) Launches Second Cancer Trial: Why This MedTech Stock Looks Like a Buy
Optiscan Imaging (ASX: OIL) has partnered with Australian Clinical Labs to launch Australia's first-in-human head and neck cancer imaging study. The ground-breaking study will recruit 50 patients at the St John of God Healthcare campus in Murdoch and will be led by prominent Perth head and neck cancer surgeon Dr Chady Sader. For investors tracking…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here